15:21:00 EDT Sun 19 May 2024
Enter Symbol
or Name
USA
CA



BioSyent Inc
Symbol RX
Shares Issued 12,290,861
Close 2023-05-17 C$ 7.60
Market Cap C$ 93,410,544
Recent Sedar Documents

BioSyent to release Q1 2023 results May 26

2023-05-18 12:39 ET - News Release

Mr. Rene Goehrum reports

BIOSYENT SCHEDULES Q1 2023 EARNINGS RELEASE FOR MAY 26, 2023

BioSyent Inc. will release its financial results for the three months ended March 31, 2023, on Friday, May 26, 2023, at 8 a.m. ET. A presentation on the company's first quarter 2023 results by Rene Goehrum, BioSyent president and chief executive officer, will also be available on the company's website on the date of release.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol RX, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other health care products that have been successfully developed, are safe and effective, and have a proven record of improving the lives of patients. BioSyent supports the health care professionals that treat these patients by marketing its products through its community, specialty and international business units.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.